At a glance
| Abbreviation | HAV |
|---|---|
| ICTV species | Hepatovirus ahepa |
| Family | Picornaviridae |
| Baltimore class | IV — (+)ssRNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: hepatovirus A1; hepatitis A virus; Hepatovirus ahepa
Riboviria › Pisuviricota › Pisoniviricetes › Picornavirales › Picornaviridae › Hepatovirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Orthornavirae |
| Phylum | Pisuviricota |
| Class | Pisoniviricetes |
| Order | Picornavirales |
| Family | Picornaviridae |
| Subfamily | Heptrevirinae |
| Genus | Hepatovirus |
| ICTV identifier | ICTV19991254 |
| NCBI taxon | 3407641 |
| Exemplar isolate | M14707 |
Host evidence
- human: 7,228 GenBank records
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
quote
RESULTS: Overall, 1436 deaths due to hepatitis A occurred, averaging 96 annually (range, 142 in 1995 to 54 in 2003).
quote
During 2017, a total of 1,521 outbreak-associated HAV cases were reported from California, Kentucky, Michigan, and Utah, with 1,073 (71%) hospitalizations and 41 (3%) deaths; most infections were among persons reporting homelessness or injection or non-injection drug use.
quote
RESULTS: Overall, the rate per 100 000 population of reported cases of hepatitis A virus infection in the United States declined 17.3-fold, from 10.4 during 1990-1998 to 0.6 during 2007-2015, and then increased to 2.8 during 2016-2020.
Lowest and highest vaccine effectiveness reported: 82% (Demicheli V 2003 Vaccine; Secondary hepatitis A cases (transmission to contacts), contacts of cases) to 100% (Werzberger A 1992 N Engl J Med; Clinically apparent hepatitis A, 2 to 16 years). Two of 6 estimates, each from its own study; not a summary figure.
- Randomised trial
- Pooled or expert review
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
- Product label observation window
- Compensation-table interval
Disease risk and vaccine efficacy: every estimate with its population, design and the sentence it came from.
Vaccines
Nothing in use found in the sources searched. That is not the same as nothing existing; see the methods page for what was searched.
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Healive (hepatitis A vacine(human diploid cell), inactivated) | Sinovac Biotech Co., Ltd | inactivated whole | Routine immunisation | Phase 3 | Not searched yet | NCT06058416 | candidateId ctgov-healive-hepatitis-a-vacine-human-diploid-cell-inacti |
| Hepatitis A vaccine (inactivated, adsorbed) | Sinovac Biotech Co., Ltd | inactivated whole | Routine immunisation | Phase 3 | Not searched yet | NCT07793227 | candidateId ctgov-inactivated-hepatitis-a-vaccine-human-diploid-cell-1 |
| Havrix® | GlaxoSmithKline | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT03183492 | candidateId ctgov-havrix-glaxosmithkline (targetDisease 'Hepatitis A') |
Antivirals
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Disease risk and vaccine efficacy — burden figures and trial results, each quoted from its source
- Hepatitis A vaccine — ingredients, schedule and reported side effects
- Vaccine pipeline — candidates listed under “Hepatitis A”
- Other Picornaviridae viruses